Alnylam Pharmaceuticals Inc
$
68.93
1.02 (1.5%)
| Volume: | 1,243,097 | Avg Vol (1m): | 974,939 |
| Market Cap $: | 7.34 Bil | Enterprise Value $: | 6.13 Bil |
| P/E (TTM): | 0.00 | P/B: | 4.71 |
| Earnings Power Value | -80.76 |
| Net Current Asset Value | 8.78 |
| Tangible Book | 14.68 |
| Projected FCF | -21.8 |
| Median P/S Value | 63.06 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 7/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 41.49 |
Cash-To-Debt ranked
lower than
50.74%
of
1078
companies
in the
Biotechnology
industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ALNY:
41.49
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 3.29, Med: 108.1, Max: 10000
Current: 41.49
|
| Equity-to-Asset | 0.77 |
Equity-to-Asset ranked
higher than
88.34%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ALNY:
0.77
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: -0.99, Med: 0.67, Max: 0.92
Current: 0.77
|
| Debt-to-Equity | 0.02 |
Debt-to-Equity ranked
higher than
91.00%
of
500
companies
in the
Biotechnology
industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
ALNY:
0.02
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: -0.07, Med: 0.06, Max: 0.33
Current: 0.02
|
| Debt-to-EBITDA | -0.04 |
Debt-to-EBITDA ranked
lower than
100.00%
of
196
companies
in the
Biotechnology
industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
ALNY:
-0.04
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: -0.37, Med: -0.06, Max: -0.04
Current: -0.04
|
| Piotroski F-Score | 3 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 6.61 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -0.84 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC -337.27%
WACC 16.43%
| ||
Profitability & Growth : 4/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -991.92 |
Operating Margin ranked
lower than
69.95%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ALNY:
-991.92
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: -1087.56, Med: -376.63, Max: -43.72
Current: -991.92
|
| Net Margin % | -929.51 |
Net Margin ranked
lower than
69.82%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ALNY:
-929.51
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -1016.58, Med: -367.56, Max: -43.5
Current: -929.51
|
| ROE % | -52.07 |
ROE ranked
higher than
52.17%
of
989
companies
in the
Biotechnology
industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ALNY:
-52.07
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -84.12, Med: -39.64, Max: -25.04
Current: -52.07
|
| ROA % | -44.68 |
ROA ranked
higher than
50.55%
of
1084
companies
in the
Biotechnology
industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ALNY:
-44.68
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -48.05, Med: -27.67, Max: -9.19
Current: -44.68
|
| ROC (Joel Greenblatt) % | -313.14 |
ROC (Joel Greenblatt) ranked
higher than
56.18%
of
1036
companies
in the
Biotechnology
industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ALNY:
-313.14
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -2120.98, Med: -353.24, Max: -238.93
Current: -313.14
|
| 3-Year Total Revenue Growth Rate | 22.20 |
3-Year Revenue Growth Rate ranked
higher than
69.89%
of
651
companies
in the
Biotechnology
industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ALNY:
15.1
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 3.75, Max: 108
Current: 15.1
|
| 3-Year Total EBITDA Growth Rate | -42.90 |
3-Year EBITDA Growth Rate ranked
lower than
56.48%
of
802
companies
in the
Biotechnology
industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ALNY:
-34.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: -65.3, Med: -1.85, Max: 62.2
Current: -34.6
|
| 3-Year EPS w/o NRI Growth Rate | -29.90 |
3-Year EPS w/o NRI Growth Rate ranked
lower than
60.55%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
ALNY:
-29.9
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
|
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -52.8, Med: -7.75, Max: 66.7
Current: -29.9
|
» ALNY's 30-Y Financials
Financials (Next Earnings Date: 2019-08-02)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:ALNY
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325412   SIC : 2834 |
| Compare | NAS:SRPT NAS:MRNA NAS:IONS NAS:SAGE OCSE:GEN NAS:SGEN NAS:BLUE SZSE:000661 NAS:JAZZ NAS:TECH HKSE:06160 NAS:NBIX HKSE:01177 SZSE:002252 HKSE:02269 TSE:4587 NAS:AMRN XAMS:GLPG NAS:EXEL OCSE:NZYM B |
| Traded in other countries | DUL.Germany 0HD2.UK |
| Address | 300 Third Street, 3rd Floor, Cambridge, MA, USA, 02142 |
| Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. Alnylam has partnered several pipeline candidates, including amyloidosis drug patisiran, hemophilia drug fitusiran, and cholesterol drug inclisiran. Up-front fees from research partnerships with firms such as Sanofi, Takeda, Roche, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see milestones and royalties from drugs commercialized under these agreements. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 4.71 |
PB Ratio ranked
lower than
64.14%
of
962
companies
in the
Biotechnology
industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ALNY:
4.71
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 2.07, Med: 5.16, Max: 21.37
Current: 4.71
|
| PS Ratio | 81.81 |
PS Ratio ranked
lower than
82.51%
of
726
companies
in the
Biotechnology
industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ALNY:
81.81
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 3.1, Med: 74.8, Max: 222.78
Current: 81.81
|
| EV-to-EBIT | -7.15 |
EV-to-EBIT ranked
lower than
100.00%
of
261
companies
in the
Biotechnology
industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ALNY:
-7.15
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -94.6, Med: -13.1, Max: -1.3
Current: -7.15
|
| EV-to-EBITDA | -7.28 |
EV-to-EBITDA ranked
lower than
100.00%
of
281
companies
in the
Biotechnology
industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ALNY:
-7.28
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -207.5, Med: -14.1, Max: -1.4
Current: -7.28
|
| EV-to-Revenue | 70.99 |
EV-to-Revenue ranked
lower than
77.82%
of
771
companies
in the
Biotechnology
industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ALNY:
70.99
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 0.7, Med: 66.2, Max: 200.5
Current: 70.99
|
| Current Ratio | 9.33 |
Current Ratio ranked
higher than
83.80%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ALNY:
9.33
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 1.88, Med: 5.63, Max: 18.24
Current: 9.33
|
| Quick Ratio | 9.12 |
Quick Ratio ranked
higher than
84.08%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ALNY:
9.12
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 1.88, Med: 5.63, Max: 18.24
Current: 9.12
|
| Days Inventory | 952.02 |
Days Inventory ranked
lower than
100.00%
of
481
companies
in the
Biotechnology
industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
ALNY:
952.02
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 952.02, Med: 2437.52, Max: 2437.52
Current: 952.02
|
| Days Sales Outstanding | 142.95 |
Days Sales Outstanding ranked
lower than
100.00%
of
668
companies
in the
Biotechnology
industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
ALNY:
142.95
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 0.57, Med: 53.29, Max: 288.31
Current: 142.95
|
| Days Payable | 1.00 |
Days Payable ranked
lower than
100.00%
of
536
companies
in the
Biotechnology
industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
ALNY:
1
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 1, Med: 12094.02, Max: 12094.02
Current: 1
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -5.90 |
3-Year Share Buyback Rate ranked
higher than
64.29%
of
857
companies
in the
Biotechnology
industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ALNY:
-5.9
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -331.8, Med: -12.55, Max: -1
Current: -5.9
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 4.70 |
Price-to-Tangible-Book ranked
lower than
55.93%
of
894
companies
in the
Biotechnology
industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ALNY:
4.7
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 2.2, Med: 5.14, Max: 15.16
Current: 4.7
|
| Price-to-Median-PS-Value | 1.09 |
Price-to-Median-PS-Value ranked
lower than
90.86%
of
678
companies
in the
Biotechnology
industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ALNY:
1.09
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.04, Med: 0.39, Max: 2.56
Current: 1.09
|
| Earnings Yield (Joel Greenblatt) % | -13.92 |
Earnings Yield (Greenblatt) ranked
higher than
51.34%
of
1081
companies
in the
Biotechnology
industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ALNY:
-13.92
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -79.2, Med: -7.6, Max: -1.1
Current: -13.92
|
More Statistics
| Revenue (TTM) (Mil) $ | 86.3 |
| EPS (TTM) $ | -7.88 |
| Beta | 2.35 |
| Volatility % | 49.11 |
| 52-Week Range $ | 60.27 - 124.22 |
| Shares Outstanding (Mil) | 101.18 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 3 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | N |